BRPI0518209A - agentes de ligação especìficos à angiopoietina-2 - Google Patents

agentes de ligação especìficos à angiopoietina-2

Info

Publication number
BRPI0518209A
BRPI0518209A BRPI0518209-3A BRPI0518209A BRPI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A
Authority
BR
Brazil
Prior art keywords
specific binding
binding agents
angiopoietin
antibodies
disclosed
Prior art date
Application number
BRPI0518209-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel Jonathon Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0518209A publication Critical patent/BRPI0518209A/pt

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0518209-3A 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2 BRPI0518209A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (fr) 2004-10-19 2005-10-19 Agents de liaison specifiques de l'angiopoietine-2

Publications (1)

Publication Number Publication Date
BRPI0518209A true BRPI0518209A (pt) 2008-11-04

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518209-3A BRPI0518209A (pt) 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2

Country Status (10)

Country Link
JP (2) JP2008520188A (fr)
CN (1) CN101495513B (fr)
BR (1) BRPI0518209A (fr)
EA (1) EA011866B1 (fr)
IL (1) IL182279A0 (fr)
MA (1) MA29015B1 (fr)
MX (1) MX2007004247A (fr)
RU (2) RU2404992C2 (fr)
SG (1) SG156668A1 (fr)
ZA (1) ZA200704020B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520188A (ja) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド アンジオポエチン−２特異的結合物質
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
BR112014007487A2 (pt) * 2011-09-30 2017-04-04 Dana Farber Cancer Inst Inc peptídeos terapêuticos
WO2013112438A1 (fr) * 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Formulations stabilisées contenant des anticorps anti-ang2
WO2014100834A1 (fr) * 2012-12-21 2014-06-26 The Regents Of The University Of California Méthodes et compositions pour le traitement de la toxicité du cyanure et de sulfure d'hydrogène
SG11201509278XA (en) * 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
IL302218B1 (en) 2014-08-28 2024-06-01 Eisai R&D Man Co Ltd Methods for the production of lanvotinib and its derivatives in a high degree of purity
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (fr) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Agent anticancéreux
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
AU2020227580A1 (en) * 2019-02-25 2021-09-30 Pharmabcine Inc. Anti-Ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487A (zh) * 2021-12-16 2023-06-20 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165115B1 (fr) * 1999-03-26 2003-05-28 Regeneron Pharmaceuticals, Inc. Modulation de la permeabilite vasculaire au moyen d'activateurs du recepteur tie2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EP2332523B8 (fr) * 2001-10-12 2022-04-20 Aquestive Therapeutics, Inc. Films uniformes pour la forme de dosage de dissolution rapide incorporant des compositions de masquage du goût
JP2008520188A (ja) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド アンジオポエチン−２特異的結合物質

Also Published As

Publication number Publication date
SG156668A1 (en) 2009-11-26
ZA200704020B (en) 2008-06-25
MX2007004247A (es) 2007-06-12
JP2008520188A (ja) 2008-06-19
JP2011207882A (ja) 2011-10-20
RU2010132956A (ru) 2012-02-10
RU2007118670A (ru) 2008-12-27
EA200700876A1 (ru) 2007-10-26
RU2404992C2 (ru) 2010-11-27
CN101495513B (zh) 2014-08-06
CN101495513A (zh) 2009-07-29
MA29015B1 (fr) 2007-11-01
EA011866B1 (ru) 2009-06-30
IL182279A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
BRPI0518209A (pt) agentes de ligação especìficos à angiopoietina-2
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
RS28904A (en) Angiopoietin-2 specific binding agents
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA201070888A1 (ru) Антитела и их производные
CR10530A (es) Anticuerpos anti-dlla4 y metodos que los usan
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
ATE512986T1 (de) Antikörper gegen clostridium difficile-toxine und ihre verwendung
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
MY174493A (en) Binding agents
MX2007013759A (es) Agentes de union de esclerostina.
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
HN2005029978A (es) Formulaciones
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.